Float Short %

17.74

Margin Of Safety %

Put/Call OI Ratio

0.42

EPS Next Q Diff

EPS Last/This Y

-0.03

EPS This/Next Y

1.66

Price

18.79

Target Price

33.75

Analyst Recom

1.25

Performance Q

69.58

Relative Volume

0.41

Beta

1.02

Ticker: URGN

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	URGN	19.74	0.38	0.34	40188
2025-08-18	URGN	19.39	0.37	0.97	28859
2025-08-19	URGN	18.9	0.37	0.41	29306
2025-08-20	URGN	19.33	0.37	0.10	29327
2025-08-21	URGN	19.77	0.37	0.06	29463
2025-08-22	URGN	19.41	0.37	0.34	29422
2025-08-25	URGN	18.48	0.37	0.80	29441
2025-08-26	URGN	19.5	0.38	0.12	29536
2025-08-27	URGN	19.5	0.38	0.00	29607
2025-08-28	URGN	19.24	0.38	0.56	29611
2025-08-29	URGN	19.45	0.38	0.01	29677
2025-09-02	URGN	19.5	0.37	0.07	30395
2025-09-03	URGN	19.35	0.37	0.77	30365
2025-09-04	URGN	18.8	0.38	0.42	30945
2025-09-05	URGN	18.88	0.38	0.00	31000
2025-09-08	URGN	21.54	0.38	0.03	31053
2025-09-09	URGN	20.69	0.37	3.60	31939
2025-09-10	URGN	19.1	0.39	1.12	32308
2025-09-11	URGN	19.25	0.40	8.95	32898
2025-09-12	URGN	18.78	0.42	0.18	33325
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	URGN	19.71	-12.1	-	-2.96
2025-08-18	URGN	19.40	-12.1	-	-2.96
2025-08-19	URGN	18.92	-12.1	-	-2.96
2025-08-20	URGN	19.30	-12.1	-	-2.96
2025-08-21	URGN	19.77	-12.1	-	-2.96
2025-08-22	URGN	19.41	-14.0	-	-2.99
2025-08-25	URGN	18.50	-14.0	-	-2.99
2025-08-26	URGN	19.50	-14.0	-	-2.99
2025-08-27	URGN	19.52	-14.0	-	-2.99
2025-08-28	URGN	19.24	-14.0	-	-2.99
2025-08-29	URGN	19.43	-14.0	-	-2.99
2025-09-02	URGN	19.52	-14.0	-	-2.99
2025-09-03	URGN	19.36	-14.0	-	-2.99
2025-09-04	URGN	18.80	-14.0	-	-2.99
2025-09-05	URGN	18.88	-14.0	-	-2.99
2025-09-08	URGN	21.42	-14.0	-	-2.99
2025-09-09	URGN	20.69	-14.0	-	-2.99
2025-09-10	URGN	19.12	-14.0	-	-2.99
2025-09-11	URGN	19.25	-14.0	-	-2.99
2025-09-12	URGN	18.79	-14.0	-	-2.99
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	URGN	-0.43	31.57	18.03
2025-08-18	URGN	-0.43	42.69	18.12
2025-08-19	URGN	-0.41	42.69	18.12
2025-08-20	URGN	-0.41	42.69	18.12
2025-08-21	URGN	-0.41	42.69	18.12
2025-08-22	URGN	-0.41	42.69	18.12
2025-08-25	URGN	-0.41	-0.70	18.12
2025-08-26	URGN	-0.41	-0.70	18.12
2025-08-27	URGN	-0.41	-0.70	17.37
2025-08-28	URGN	-0.41	-0.70	17.37
2025-08-29	URGN	-0.41	-0.70	17.37
2025-09-02	URGN	-0.41	-0.69	17.37
2025-09-03	URGN	-0.41	-0.69	17.37
2025-09-04	URGN	-0.41	-0.69	17.37
2025-09-05	URGN	-0.41	-0.69	17.37
2025-09-08	URGN	-0.41	-0.69	17.37
2025-09-09	URGN	-0.41	-0.69	17.37
2025-09-10	URGN	-0.45	-0.69	17.37
2025-09-11	URGN	-0.45	-0.69	17.74
2025-09-12	URGN	-0.45	-0.69	17.74
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.63

Avg. EPS Est. Next Quarter

-0.39

Insider Transactions

-0.45

Institutional Transactions

-0.69

Beta

1.02

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

33.4

Max Drawdown 5-Year %

-85.4

Target Price

33.75

P/E

Forward P/E

PEG

P/S

9.22

P/B

P/Free Cash Flow

EPS

-3.32

Average EPS Est. Cur. Y

-2.99

EPS Next Y. (Est.)

-1.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-164.44

Relative Volume

0.41

Return on Equity vs Sector %

273.1

Return on Equity vs Industry %

286.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.11

EBIT Estimation

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 253

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y